Danielle Ogilvie
Family · New Castle, INNPI 1376017665
Payments from drug & device makers
Across 190 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$633
- Novo Nordisk$485
- Lilly USA, LLC$318
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$182
- GSK$130
- Otsuka America Pharmaceutical, Inc.$129
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $633 |
| Novo Nordisk | 32 | $485 |
| Lilly USA, LLC | 21 | $318 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $182 |
| GSK | 8 | $130 |
| Otsuka America Pharmaceutical, Inc. | 6 | $129 |
| Pfizer | 6 | $126 |
| Bayer | 7 | $106 |
| Boehringer Ingelheim | 5 | $88 |
| Exact Sciences | 5 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $64 |
| Axsome Therapeutics, Inc. | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| Alnylam Pharmaceuticals Inc. | 3 | $60 |
| Corium, LLC | 4 | $51 |
| Lundbeck LLC | 3 | $46 |
| Novartis | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 8 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| AstraZeneca | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Medtronic | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Biogen | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Covis Pharma GmbH | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,970 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $140,660 |
| JardianceEmpagliflozin | 70 | $85,091 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $68,921 |
| MounjaroTirzepatide | 27 | $39,757 |
| TrulicityDulaglutide | 12 | $25,603 |
| EliquisApixaban | 23 | $22,408 |
| VraylarCariprazine Hcl | 11 | $21,169 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $14,672 |
| MyrbetriqMirabegron | 19 | $13,120 |
| FarxigaDapagliflozin Propanediol | 13 | $9,919 |
| VascepaIcosapent Ethyl | 13 | $9,066 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,055 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $6,420 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $4,526 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $485 | $140,660100 claims |
| Boehringer IngelheimJardiance | $88 | $85,09170 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $130 | $76,97683 claims |
| Lilly USA, LLCMounjaro, Trulicity | $318 | $65,36039 claims |
| PfizerEliquis | $126 | $22,40823 claims |
| AbbVieVraylar | $633 | $21,16911 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $13,12019 claims |
| AstraZenecaFarxiga | $33 | $9,91913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in New Castle
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.